3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Leukemia
4
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Cytokine Release Syndrome
2
Triple Negative Breast Neoplasms
1
Primary Immunodeficiency Diseases
1
Osteopetrosis
1
Neurotoxicity Syndromes
1
Neoplasm, Residual
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Graft vs Host Disease
1
Epstein-Barr Virus Infections
1
Cytopenia
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Aplastic
1
Interventions
Cyclophosphamide
12
fludarabine
11
fludarabine phosphate
8
Tacrolimus
8
Melphalan
8
Whole-Body Irradiation
7
Mycophenolic Acid
7
Thiotepa
6
Imatinib Mesylate
6
nilotinib
5
Granulocyte Colony-Stimulating Factor
5
Dasatinib
5
Busulfan
5
venetoclax
4
ponatinib
4
asciminib
4
Mesna
4
bosutinib
3
Sirolimus
3
Peripheral Blood Stem Cell Transplantation
3
thymoglobulin
2
ruxolitinib
2
blinatumomab
2
Patient Reported Outcome Measures
2
Filgrastim
2
Antilymphocyte Serum
2
selinexor
1
plerixafor
1
Triamcinolone
1
Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
AP 1903 reagent
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled